Alliance Pharma plc

LSE APH.L

Alliance Pharma plc Goodwill for the year ending December 31, 2023: USD 18.43 M

Alliance Pharma plc Goodwill is USD 18.43 M for the year ending December 31, 2023, a -29.16% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Alliance Pharma plc Goodwill for the year ending December 31, 2022 was USD 26.02 M, a -38.45% change year over year.
Alliance Pharma plc Goodwill for the year ending December 31, 2021 was USD 42.27 M, a -0.98% change year over year.
Alliance Pharma plc Goodwill for the year ending December 31, 2020 was USD 42.69 M, a 94.88% change year over year.
Alliance Pharma plc Goodwill for the year ending December 31, 2019 was USD 21.91 M, a 3.80% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

LSE: APH.L

Alliance Pharma plc

CEO	Mr. Nicholas John Sedgwick
IPO Date	Nov. 22, 2001
Location	United Kingdom
Headquarters	Avonbridge House
Employees	290
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.

Key trends

Past 5 years